Maa: Yhdysvallat
Kieli: englanti
Lähde: NLM (National Library of Medicine)
donepezil hydrochloride (UNII: 3O2T2PJ89D) (donepezil - UNII:8SSC91326P)
Eisai Inc.
donepezil hydrochloride
SOLUTION
1 mg in 1 mL
ORAL
PRESCRIPTION DRUG
ARICEPT® is indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild to moderate Alzheimer's Disease, as well as in patients with severe Alzheimer's Disease. ARICEPT® is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives.
ARICEPT® Oral Solution is a clear, colorless to light yellow solution containing 1 mg of donepezil hydrochloride in each mL (1 mg/mL). Each teaspoon (5mL) contains 5 mg of donepezil hydrochloride. NDC#62856-851-30 300 mL HDPE Bottles Storage: Store at controlled room temperature, 15°C to 30°C (59°F to 86°F). RX only ARICEPT® is a registered trademark of Eisai Co., Ltd. Manufactured and Marketed by Eisai Inc., Teaneck, NJ 07666 Marketed by Pfizer Inc, New York, NY 10017 © 2006 Eisai Inc. Printed in U.S.A. Revised October 2006
ARICEPT- DONEPEZIL HYDROCHLORIDE SOLUTION EISAI INC. ---------- ARICEPT® ORAL SOLUTION (DONEPEZIL HYDROCHLORIDE) DESCRIPTION ARICEPT® (donepezil hydrochloride) is a reversible inhibitor of the enzyme acetylcholinesterase, known chemically as (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1_H_- inden-1-one hydrochloride. Donepezil hydrochloride is commonly referred to in the pharmacological literature as E2020. It has an empirical formula of C H NO HCl and a molecular weight of 415.96. Donepezil hydrochloride is a white crystalline powder and is freely soluble in chloroform, soluble in water and in glacial acetic acid, slightly soluble in ethanol and in acetonitrile and practically insoluble in ethyl acetate and in n-hexane. Each 1mL of ARICEPT® Oral Solution contains 1 mg of donepezil hydrochloride. ARICEPT® Oral Solution also contains sorbitol solution 70%, povidone K-30, citric acid anhydrous, sodium citrate dihydrate, sodium benzoate, methylparaben, propylene glycol, sodium metabisulfite, purified water and strawberry flavor. CLINICAL PHARMACOLOGY Current theories on the pathogenesis of the cognitive signs and symptoms of Alzheimer's Disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. There is no evidence that donepezil alters the course of the underlying dementing process. CLINICAL TRIAL DATA The effectiveness of ARICEPT® as a treatment for Alzheimer's Disease is demonstrated by the results of randomized, double-blind, placebo-controlled clinical investigations in mild, moderate and severe patients with Alzheimer's Disease. MILD-MODERATE ALZHEIMER'S DISEASE The effectiveness of ARICEPT® as a treatment for Alzheimer's Disease is demonstrated by the results of two randomized, double-blind, placebo-controlle Lue koko asiakirja